• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞毒性药物对特发性膜性肾病有益吗?对照试验的荟萃分析。

Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials.

作者信息

Imperiale T F, Goldfarb S, Berns J S

机构信息

Department of Medicine, Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA.

出版信息

J Am Soc Nephrol. 1995 Feb;5(8):1553-8. doi: 10.1681/ASN.V581553.

DOI:10.1681/ASN.V581553
PMID:7756587
Abstract

The use of cytotoxic agents for the treatment of idiopathic membranous nephropathy is controversial. Although several controlled trials have been published, both the comparison groups and the study findings have varied, resulting in clinical uncertainty. To explore this uncertainty, a meta-analysis of controlled trials of treatment with cyclophosphamide or chlorambucil was performed in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria. Patients in the control groups received only symptomatic treatment or corticosteroids. Descriptive and quantitative data from each trial were abstracted independently. Outcomes included effects of treatment on renal function and proteinuria, with a complete remission (CR) or partial remission (PR) defined as the complete or partial resolution of proteinuria without deterioration of renal function. For patients having either any response (CR or PR) or only a CR, both the relative risk (RR) and the number needed to be treated were calculated. The five trials that satisfied criteria for inclusion in the analysis were clinically and statistically homogeneous. There were no placebo-controlled trials that met the criteria for inclusion. Among the 228 patients in these studies, the RR of achieving any response with cytotoxic agents was 2.3 (95% confidence interval, 1.7 to 3.2) and the RR for a CR was 4.6 (95% confidence interval, 2.2 to 9.3), with respective numbers needed to be treated of 2.9 and 4.7, meaning that between three and five patients would need to be treated with cytotoxic agents to achieve one response. Exclusion of the only nonrandomized trial had no significant effect on the results. Both chlorambucil and cyclophosphamide showed similar beneficial effects.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

使用细胞毒性药物治疗特发性膜性肾病存在争议。尽管已经发表了几项对照试验,但比较组和研究结果各不相同,导致临床存在不确定性。为探究这种不确定性,对特发性膜性肾病和肾病范围蛋白尿患者使用环磷酰胺或苯丁酸氮芥进行治疗的对照试验进行了荟萃分析。对照组患者仅接受对症治疗或皮质类固醇治疗。每个试验的描述性和定量数据均独立提取。结局包括治疗对肾功能和蛋白尿的影响,完全缓解(CR)或部分缓解(PR)定义为蛋白尿完全或部分消退且肾功能无恶化。对于有任何反应(CR或PR)或仅有CR的患者,计算相对风险(RR)和需要治疗的人数。符合纳入分析标准的五项试验在临床和统计学上具有同质性。没有符合纳入标准的安慰剂对照试验。在这些研究中的228例患者中,使用细胞毒性药物获得任何反应的RR为2.3(95%置信区间,1.7至3.2),CR的RR为4.6(95%置信区间,2.2至9.3),相应的需要治疗的人数分别为2.9和4.7,这意味着需要三到五名患者接受细胞毒性药物治疗才能获得一次反应。排除唯一的非随机试验对结果无显著影响。苯丁酸氮芥和环磷酰胺均显示出相似的有益效果。(摘要截短于250字)

相似文献

1
Are cytotoxic agents beneficial in idiopathic membranous nephropathy? A meta-analysis of the controlled trials.细胞毒性药物对特发性膜性肾病有益吗?对照试验的荟萃分析。
J Am Soc Nephrol. 1995 Feb;5(8):1553-8. doi: 10.1681/ASN.V581553.
2
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.一项比较甲基强的松龙联合苯丁酸氮芥与甲基强的松龙联合环磷酰胺治疗特发性膜性肾病的随机研究。
J Am Soc Nephrol. 1998 Mar;9(3):444-50. doi: 10.1681/ASN.V93444.
3
Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.特发性膜性肾病免疫抑制治疗的比较有效性和耐受性:一项网状Meta分析。
PLoS One. 2017 Sep 12;12(9):e0184398. doi: 10.1371/journal.pone.0184398. eCollection 2017.
4
Treatment of membranous nephropathy.
Nephrol Dial Transplant. 2001;16 Suppl 5:8-10. doi: 10.1093/ndt/16.suppl_5.8.
5
Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy.皮质类固醇、环磷酰胺及苯丁酸氮芥治疗膜性肾病
Semin Nephrol. 2003 Jul;23(4):355-61. doi: 10.1016/s0270-9295(03)00052-4.
6
Treatment of the nephrotic syndrome with cyclosporin A.用环孢素A治疗肾病综合征。
J Autoimmun. 1992 Apr;5 Suppl A:315-24. doi: 10.1016/0896-8411(92)90049-v.
7
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.成人肾病综合征特发性膜性肾病的免疫抑制治疗
Cochrane Database Syst Rev. 2004 Oct 18(4):CD004293. doi: 10.1002/14651858.CD004293.pub2.
8
Cyclophosphamide provides no additional benefit to steroid therapy in the treatment of idiopathic membranous nephropathy.在特发性膜性肾病的治疗中,环磷酰胺相较于类固醇疗法并无额外益处。
Am J Kidney Dis. 1993 May;21(5):497-503. doi: 10.1016/s0272-6386(12)80395-7.
9
20 years after methylprednisolone/chlorambucil treatment in idiopathic membranous nephropathy stage II-III with nephrotic syndrome.在患有肾病综合征的特发性膜性肾病II - III期接受甲基强的松龙/苯丁酸氮芥治疗20年后。
Prilozi. 2006 Dec;27(2):5-12.
10
Cyclophosphamide or chlorambucil therapy is indicated in idiopathic membranous nephropathy with strong risk factors for progression.
Am J Kidney Dis. 2005 Apr;45(4):788-9; author replyy 789-90. doi: 10.1053/j.ajkd.2005.01.033.

引用本文的文献

1
Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial.咪唑立宾治疗难治性肾病综合征的疗效与安全性:一项多中心、对照、开放标签、随机对照试验方案
JMIR Res Protoc. 2023 Jun 16;12:e46101. doi: 10.2196/46101.
2
Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.膜性肾病的治疗:新旧千年的故事
Front Immunol. 2022 Mar 1;13:789713. doi: 10.3389/fimmu.2022.789713. eCollection 2022.
3
Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
成人肾病综合征中原发性膜性肾病的免疫抑制治疗。
Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.
4
Treatment of primary membranous nephropathy: where are we now?原发性膜性肾病的治疗:我们现在在哪里?
J Nephrol. 2018 Aug;31(4):489-502. doi: 10.1007/s40620-017-0427-5. Epub 2017 Sep 5.
5
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.成人肾病综合征特发性膜性肾病的免疫抑制治疗
Cochrane Database Syst Rev. 2014 Oct 16;2014(10):CD004293. doi: 10.1002/14651858.CD004293.pub3.
6
Chapter 7: Idiopathic membranous nephropathy.第7章:特发性膜性肾病。
Kidney Int Suppl (2011). 2012 Jun;2(2):186-197. doi: 10.1038/kisup.2012.20.
7
Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.免疫抑制治疗膜性肾病:36 项临床试验的系统评价和荟萃分析。
Clin J Am Soc Nephrol. 2013 May;8(5):787-96. doi: 10.2215/CJN.07570712. Epub 2013 Feb 28.
8
Evidence-based practice guideline for the treatment of CKD.慢性肾脏病治疗的循证实践指南
Clin Exp Nephrol. 2009 Dec;13(6):537-66. doi: 10.1007/s10157-009-0237-8.
9
Membranous nephropathy in children: clinical presentation and therapeutic approach.儿童膜性肾病:临床表现与治疗方法。
Pediatr Nephrol. 2010 Aug;25(8):1419-28. doi: 10.1007/s00467-009-1324-5. Epub 2009 Nov 12.
10
Idiopathic membranous nephropathy: management strategies.特发性膜性肾病:治疗策略
Drugs. 2009 Jul 9;69(10):1303-17. doi: 10.2165/00003495-200969100-00002.